SCHEMBL22658607

SCHEMBL22658607

CC(C)C1CN(c2ncc(Br)nn2)CCN1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.46
ROCK2 O75116 3/20 0.42
ROCK1 Q13464 3/20 0.42
HDAC1 Q13547 1/20 0.39
PRKCQ Q04759 3/20 0.38
PRKCD Q05655 1/20 0.38
SPAST Q9UBP0 1/20 0.36
NMT1 P30419 1/20 0.35
ZAP70 P43403 1/20 0.34
TLR9 Q9NR96 1/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
CDK4 P11802 1/20 0.32
CCND1 P24385 1/20 0.32
CDK2 P24941 1/20 0.32
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22658606 1.00 HTT (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL82195 0.80 HTT (0.49) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL31082993 0.78 PRKCQ (0.37) HTTROCK2ROCK1PRKCQCHRNB2
SCHEMBL29465145 0.78 ROCK2 (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL30534249 0.78 ROCK2 (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL22658659 0.78 ROCK2 (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL30534239 0.78 ROCK2 (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL22658660 0.78 ROCK2 (0.46) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL19035699 0.77 PRKCQ (0.49) HTTROCK2ROCK1HDAC1PRKCQ
SCHEMBL4725933 0.77 HDAC1 (0.43) HTTROCK2ROCK1HDAC1PRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
EP-3969446-B1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2023-09-27 EP disclosed
EP-4219466-A1 COMPUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-08-02 EP disclosed
US-20230234942-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2023-07-27 US disclosed
CN-115768762-A Compounds for the treatment of huntington's disease PTC医疗公司 2023-03-07 CN disclosed
US-20220204478-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2022-06-30 US disclosed
CN-114245794-A Compounds for the treatment of huntington's disease PTC医疗公司 2022-03-25 CN disclosed
EP-3969446-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2022-03-23 EP disclosed
WO-2020231977-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. (US) 2020-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204478-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, FH HTT 1/4885ROCK2 3535/4885ROCK1 3829/4885
US-20230234942-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, CLN6 HTT 1/4885ROCK2 3864/4885ROCK1 3949/4885
US-12577226-B2 Compounds for treating Huntington's disease HTT, HYPK, GRIN2C HTT 1/4885ROCK2 3768/4885ROCK1 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.